**References**

1. Andrae et al. 2008. Screening-Preventable Cervical Cancer Risks: Evidence from a Nationwide Audit in Sweden.
2. Arbyn et al. 2008. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. *British Medical Journal*. 337:a1284.
3. Arbyn et al. 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. *Vaccine*. 30 Suppl 5: F88-99.
4. Blatt et al. Comparison of Cervical Cancer Screening Results among 256, 648 women in multiple clinical practices. *Cancer Pathology* 123 (5): 282-288
5. Brotherton et al. 2011. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. *The Lancet Oncology*. 377(9783):2085-92.
6. Castanon et al. 2014. Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. 2014 PLoS Medicine/ Public Library of Science. 11(1):e1001585.
7. Castle et al. 2011. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *The Lancelot Oncology:* 12:9. 880-890.
8. Cox et al. 2013. Comparison of cervical cancer screening strategies incorporating different combinations of cytology. HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. *Am J Obstet* *Gynecol* 2013; 208:184.e1-11.
9. Crowe et al. 2014. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. *British Medical Journal.* 348:g1458, 2014.
10. Cuzick J, Castanon A, Sasieni P. 2010. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormailities in women aged 20-29 in the UK. *British Journal of Cancer* 102: 933-939.
11. Dudding N, Crossley J. Sensitivity and specificity of HPV testing what are the facts? Editorial Cytopathology 24:283-288
12. Elfstrom et al. 2014. Long term duration of protective effect of HPV negative women: follow up of primary HPV screening randomised control trial. *British Medical Journal*: 348.
13. Franco EL, Cuzick J. 2008. Cervical cancer screening following prophylactic human papillomavirus vaccination. *Vaccine* 26 (Suppl 1):A16-23.
14. Gertig et al. 2013. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. *BMC Medicine*. 11:227, 2013.
15. Katki H et al. 2013. 5 year risks of CIN3+ and cervical cancer among women who test PAP negative but are HPV positive. *Journal of Lower Genital Tract Disease.* 17(Suppl 1):S56-63.
16. Katki et al. 2011. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology; a population-based study in routine clinical practice. *The Lancet Oncology* Volume 12, Issue 7, 663-672.
17. Khan et al. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing clinical practice. *Journal of the National Cancer Institute*. 97 (14): 1072-9, 2005 Jul 20.
18. Kitchener HC, Almonte M, Thomson C et al. 2009. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC); a randomised controlled trial. *The Lancelot Oncology* 10:672-82
19. Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. *Health Technol Assess.* 2014 Apr: 18(23):1-196
20. Kyrgiou et al. 2006. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systemative review and meta-analysis. *Lancet*. 367 (9509):489-98.
21. Landy R, Birke H, Castanon A, Sasieni P. 2014. Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. *British Medical Journal* 110, 1841-1846.
22. Leinonen et al. 2012. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirua DNA testing: prospective randomised trial in Finland. *BMJ*. 2012 Nov 29;345;e7789.
23. Lonnberg et al. 2013. Mortality audit of the Finnish cervical cancer screening program. *International Journal of Cancer.* 132(9):2134-40, 2013 May 1.
24. Ogilvie et al. 2012. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial- the HPV FOCAL Study. *British Journal of Cancer* 107, 1917-1924.
25. Patel et al. 2012. Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. *British Journal of Cancer* 106, 1753-1759.
26. Rijkaart DC, Berkhof J, Rozendaal L, et al. 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. *Lancet: Oncology* 13(1): 78-88.
27. Ronco G, Giorgi-Rossi P, Carozzi F, et al. 201. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a trandomised controlled trial. *Lancet: Oncology* 11(3): 249-57.
28. Ronco, G et al. 2013. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up four European randomised controlled trials. *The Lancet Volume* 383, No. 9916, p524-532.
29. Sasieni and Castanon. 2012. Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20-24. *Journal of Medical Screening.* 19(3):127-32.
30. Sasieni P, Castanon A, Cuzick J, Snow J. 2009. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *British Medical Journal* 339: b2968.
31. Shiffman and Wentzensen. 2016. A suggested approach to simply and improve cervical screening in the United States. *Journal of Lower Genital Tract Disease*. 20(1):1-7 Editorial.
32. Tabrizi SN, Brotherton JM, Kaldor JM, et al. 2014. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. *Lancet: Infectious Diseases* 14(10):958-66.
33. Warner KH, et al. 2015. Use of primary high-risk human papillomavirus testing for cervical. *Gynaecological Oncology* 136 (2015) 178-192.
34. Wright TC et al. 2015. End of study results from the ATHENA study using HPV as the first-line screening test. Elsevier Inc. (http://creativecommons.org/licneses/by-nc-sa/3.0/).